Guangzhou Wondfo Biotech Overview
- Year Founded
-
1992
- Status
-
Public
- Employees
-
2,443
- Stock Symbol
-
300482
- Investments
-
11
- Share Price
-
$2.15
- (As of Friday Closing)
Guangzhou Wondfo Biotech General Information
Description
Guangzhou Wondfo Biotech Co Ltd is engaged in the research, development, production and sales of POCT-related products such as rapid diagnostic reagents and rapid testing instruments. Its products are sold in various countries and regions, and are widely used in clinical testing, critical care, chronic disease management, primary healthcare, epidemic monitoring, disaster relief, on-site law enforcement, and family and personal health management.
Contact Information
Website
www.wondfo.comCorporate Office
- Number 8 Lizhishan Road, Science City
- Luogang District
- Guangzhou, Guangdong 510641
- China
Corporate Office
- Number 8 Lizhishan Road, Science City
- Luogang District
- Guangzhou, Guangdong 510641
- China
Guangzhou Wondfo Biotech Stock Performance
As of 20-Nov-2026, Guangzhou Wondfo Biotech’s stock price is $2.15. Its current market cap is $1.01B with 468M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $2.15 | $2.25 | $2.14 - $3.77 | $1.01B | 468M | 5.12M | -$0.02 |
Guangzhou Wondfo Biotech Financials Summary
As of 30-Sep-2026, Guangzhou Wondfo Biotech has a trailing 12-month revenue of $285M.
|
In Thousands, USD |
TTM 30-Sep-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 958,102 | 1,184,783 | 1,281,796 | 1,707,171 |
| Revenue | 285,164 | 290,187 | 427,124 | 390,807 |
| EBITDA | (3,584) | 23,951 | 127,328 | 115,931 |
| Net Income | (9,123) | (8,764) | 78,271 | 68,923 |
| Total Assets | 900,709 | 943,542 | 980,076 | 814,225 |
| Total Debt | 1,476 | 85,991 | 81,022 | 84,578 |
Guangzhou Wondfo Biotech Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Guangzhou Wondfo Biotech Patents
Guangzhou Wondfo Biotech Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026016918-A1 | Nucleic acid test cartridge | Pending | 15-Jul-2024 | ||
| WO-2026016920-A1 | Nucleic acid test cartridge and nucleic acid test method | Pending | 15-Jul-2024 | ||
| WO-2025189788-A1 | Incubation device and chemiluminescence immunoassay analyzer | Pending | 13-Mar-2024 | ||
| WO-2025189789-A1 | Incubation reaction device and in-vitro diagnosis analysis system | Pending | 13-Mar-2024 | ||
| WO-2025189790-A1 | Sample analyzer, loading device and temporary-storage mechanism | Pending | 11-Mar-2024 | G01N35/025 |
Guangzhou Wondfo Biotech Signals
Guangzhou Wondfo Biotech Investments & Acquisitions (11)
Guangzhou Wondfo Biotech’s most recent deal was a Early Stage VC with PolySeq for . The deal was made on 16-Mar-2026.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| PolySeq | 16-Mar-2026 | Early Stage VC | Enterprise Systems (Healthcare) | ||
| PolySeq | 12-May-2023 | Early Stage VC | Enterprise Systems (Healthcare) | ||
| Tisenc | 29-Jan-2022 | Merger/Acquisition | Diagnostic Equipment | ||
| Jiaohong Biotech | 05-Aug-2021 | Early Stage VC | Diagnostic Equipment | ||
| Cells Vision | 11-Jun-2021 | Early Stage VC | Decision/Risk Analysis |
Guangzhou Wondfo Biotech ESG
Risk Overview
Risk Rating
Updated October, 31, 2025
33.18 | High Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 14,999
Rank
Percentile
Healthcare
Industry
of 665
Rank
Percentile
Medical Devices
Subindustry
of 235
Rank
Percentile
Guangzhou Wondfo Biotech Exits (1)
Guangzhou Wondfo Biotech’s most recent exit was on 23-Jan-2017 from Binx. The exit was categorized as with 9 buyers.
| Company Name | Exit Date | Exit Type | Exit Size | Status | Buyers |
|---|---|---|---|---|---|
| Binx | 23-Jan-2017 | Completed |
|
Guangzhou Wondfo Biotech Affiliates
Subsidiaries (1)
| Name | Industry | Location | Year Founded |
|---|---|---|---|
| Baishikang Biological Technology | Ningbo, China | 2017 |
Guangzhou Wondfo Biotech FAQs
-
When was Guangzhou Wondfo Biotech founded?
Guangzhou Wondfo Biotech was founded in 1992.
-
Where is Guangzhou Wondfo Biotech headquartered?
Guangzhou Wondfo Biotech is headquartered in Guangzhou, China.
-
What is the size of Guangzhou Wondfo Biotech?
Guangzhou Wondfo Biotech has 2,443 total employees.
-
What industry is Guangzhou Wondfo Biotech in?
Guangzhou Wondfo Biotech’s primary industry is Other Healthcare Technology Systems.
-
Is Guangzhou Wondfo Biotech a private or public company?
Guangzhou Wondfo Biotech is a Public company.
-
What is Guangzhou Wondfo Biotech’s stock symbol?
The ticker symbol for Guangzhou Wondfo Biotech is 300482.
-
What is the current stock price of Guangzhou Wondfo Biotech?
As of 20-Nov-2026 the stock price of Guangzhou Wondfo Biotech is $2.15.
-
What is the current market cap of Guangzhou Wondfo Biotech?
The current market capitalization of Guangzhou Wondfo Biotech is $1.01B.
-
What is Guangzhou Wondfo Biotech’s current revenue?
The trailing twelve month revenue for Guangzhou Wondfo Biotech is $285M.
-
What is Guangzhou Wondfo Biotech’s annual earnings per share (EPS)?
Guangzhou Wondfo Biotech’s EPS for 12 months was -$0.02.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process